The recall occurs just weeks after Pfizer completed a $3.6 billion acquisition of King Pharmaceuticals, whose portfolio included the painkiller Embeda. Pfizer is pulling the drug because of a defect in a component called naltexone, which is meant to deter misuse or abuse of the drug, according to the news report.
Due to the stability defect, the drug will likely be unavailable for several months. Pfizer officials have said the recall does not significantly affect the value of the acquisition because “there are other assets that make this a good deal for us,” according to the news report.
Read the news report about the recall of Embeda.
Read other coverage about recalls:
– Triad to Shut Down Healthcare Line Following Recalls
– Smith & Nephew Recalls IV Prep Antiseptic Wipes
– FDA Defends Actions Regarding Triad Sterile Lubricating Jelly
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.